N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

Sponsor: Pfizer • ClinicalTrials.gov ID: NCT07765888

Registry updated: 2026-10-15
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema (also called atopic dermatitis) is a common skin condition that makes the skin dry, itchy, red, and irritated. * This study is seeking participants who: Are aged 12 years or older. * Were confirmed to have atopic dermatitis (AD) at least 12 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD. Participants in this study will randomly receive either tilrekimig or placebo at a 2:1 ratio. A placebo does not have any medicine in it but looks just like the medicine being studied. The study treatment period will be 24 weeks. The last dose of study treatment will be administered at week 20. Some participants will join the long-term extension study C4531008 at week 24. A long-term extension study is an additional study that participants may be able to join after completing the main study. It allows researchers to continue collecting information about how well the study medicine works and how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last study treatment dose.

Interventions

  • Tilrekimig (Drug)
    Subcutaneous Injections at required timepoints
  • Placebo (Drug)
    Subcutaneous Injections at required timepoints

Eligibility criteria

Inclusion Criteria: * Participants 12 years of age or older * Must meet the following AD criteria: 1. Clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 12 months prior to Day 1 2. An inadequate response to standard of care treatments {eg, at least medium potency topical corticosteroids (TCS)} consistent with AD treatment guidelines 3. Moderate-to-severe eczema for at least 1 year * Adolescent participants must be up to date on immunizations per local guidance. Exclusion Criteria: * Clinically Significant Autoimmune Disease * Significant Infection History or Active Infection * Known or Suspected Immunodeficiency/Immunosuppression * Significant psychiatric illness or suicidality * Clinically significant hepatic, renal, or hematologic abnormalities

Conditions

Atopic Dermatitis

Locations

  • Cahaba Dermatology & Skin Health Center — Birmingham, Alabama, United States
  • ORSO Health — Scottsdale, Arizona, United States
  • Kern Research, Inc. — Bakersfield, California, United States
  • Northridge Clinical Trials — Northridge, California, United States
  • University Clinical Trials, Inc — San Diego, California, United States
  • Focus Clinical Research — West Hills, California, United States
  • Pediatric Skin Research — Miami, Florida, United States
  • AllerVie Clinical Research — Panama City, Florida, United States
  • GCP Research , Global Clinical Professionals — St. Petersburg, Florida, United States
  • Marietta Dermatology Clinical Research, Inc. — Marietta, Georgia, United States
  • Aeroallergy Research Laboratories of Savannah, Inc — Savannah, Georgia, United States
  • Red River Research Partners LLC — Fargo, North Dakota, United States
  • Derm Texas — Dallas, Texas, United States
  • Stryde Research-Epiphany Dermatology — Southlake, Texas, United States
  • Charme Clinique — Matsudo, Chiba, Japan
  • Miyata Dermatology Clinic — Matsudo, Chiba, Japan
  • Shibaki Dermatology Clinic — Teine-ku, Hokkaido, Japan
  • Aile Home Clinic Nagaoka — Nagaoka, Niigata, Japan
  • Dermatology and Ophthalmology Kume Clinic — Sakai, Osaka, Japan
  • NTT Medical Center Tokyo — Shinagawa, Tokyo, Japan
  • Osaka Metropolitan University Hospital — Osaka, Japan
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record